Retinal vein occlusion occurrence is rare after COVID-19 vaccine

Article

A recent study aimed to set the record straight on the occurrence of retinal vein occlusions (RVOs) following messenger RNA COVID-19 vaccinations.

©Krakenimages.com / stock.adobe.com
The investigators sought to determine how often patients are diagnosed with new RVO acutely after the first messenger RNA COVID-19 vaccine compared with other commonly administered vaccines. (©Krakenimages.com / stock.adobe.com)

A large cohort study found that there is no association between the first messenger RNA (mRNA) COVID-19 vaccinations and acute retinal vein occlusion (RVO),1 according to first author Ian Dorney, BS, from Case Western Reserve University School of Medicine, Cleveland, Ohio, US.

A few of the recent case reports2-5 on the topic have suggested an association between the development of new-onset RVO and mRNA COVID-19 vaccinations. Because of the negative impact of RVOs on vision, the authors of the study under discussion considered that an epidemiologic investigation was important to determine the impact of the vaccinations on the public health.

The investigators sought to determine how often patients are diagnosed with new RVO acutely after the first mRNA COVID-19 vaccine compared with other very commonly administered vaccines, ie, influenza and tetanus, diphtheria, pertussis (Tdap) vaccines.

The data from the electronic health records of more than 103 million patients were included in this retrospective population-based cohort study. The data were searched for vaccination Common Procedural Technology codes and newly diagnosed RVO within 21 days of vaccination, and the relative risks were determined. The primary outcomes was the development of RVO with 21 days of vaccination.

The analysis showed that 0.003% of patients had a new diagnosis of RVO within 21 days after receiving a mRNA COVID-19 vaccination, and the vaccination was not associated with development of RVO.

References
  1. Dorney I, Shaia J, Kaelber DC, et al. Risk of new retinal vascular occlusion after mRNA COVID-19 vaccination within aggregated electronic health record data. JAMA Ophthalmol. Published online April 13, 2023. doi:10.1001/jamaophthalmol.2023.0610
  2. Abdin AD, Gärtner BC, Seitz B. Central retinal artery occlusion following COVID-19 vaccine administration. Am J Ophthalmol Case Rep. 2022;26:101430; doi:10.1016/j.ajoc.2022.101430
  3. Pur DR, Catherine Danielle Bursztyn LL, Iordanous Y. Branch retinal vein occlusion in a healthy young man following mRNA COVID-19 vaccination. Am J Ophthalmol Case Rep. 2022;26:101445; doi:10.1016/j.ajoc.2022.101445
  4. Su CK, Au SCL. Isolated and combined unilateral central retinal artery and vein occlusions after vaccination: a review of the literature. J Stroke Cerebrovasc Dis. 2022;31:106552; doi:10.1016/j.jstrokecerebrovasdis.2022.106552
  5. Endo B, Bahamon S, Martínez-Pulgarín DF. Central retinal vein occlusion after mRNA SARS-CoV-2 vaccination: a case report. Indian J Ophthalmol. 2021;69:2865-2866; doi:10.4103/ijo.IJO_1477_21
Recent Videos
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
AAO 2024: Bonnie An Henderson, MD, talks about advancing medical education with AI, robotics, and diverse learning methods
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.